Netarsudil-latanoprost (Roclanda) recently received a positive HSE decision following rapid review by the National Centre for Pharmacoeconomics (NCPE), meaning that it is now approved for reimbursement for treatment of glaucoma patients in Ireland.

Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG) or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. 

The therapy is a fixed-dose combination of both netarsudil and latanoprost, and is a novel Rho-kinase (ROCK) inhibitor, which reduces intraocular pressure (IOP). The treatments also target trabecular meshwork (TM) dysfunction.

Each millilitre of solution contains 50mcg latanoprost and 200mcg netarsudil (as mesylate). These two active substances lower the pressure in the eye in different ways. Latanoprost is a prostaglandin analogue that works by increasing the drainage of fluid out of the eye. Netarsudil blocks the activity of the enzyme Rho kinase, which has a role in controlling fluid drainage from the eye. By blocking this enzyme, netarsudil increases the flow of fluid out of the eyeball, thereby lowering pressure inside the eye. Together, the two active substances reduce the pressure inside the eye more than either medicine alone. 

Roclanda represents the first new class of medication for medical management of glaucoma in Europe in 25 years, and signifies a new direction for the management of glaucoma for Irish patients. POAG affects over 100,000 adults across Ireland, as of 2024, with its prevalence increasing with age.

Roclanda is marketed in Ireland by Santen.